Narrator: This is Science Today. Although there
are a number of cancers which are called "chemotherapy-responsive"
- the sad truth is, they're not the majority of cases.
That's why many cancer researchers, including Dr.
Robert Figlin of UCLA, are looking at immunotherapy
to play a bigger role in cancer treatment.
Figlin: The natural idea would be, if you can
enhance their immune system so that their immune system
is now observing the development of cancer and hopefully
destroying it as it develops, then you have a surveillance
mechanism that enhances the patient's chances for
Narrator: Because of the recent advances in
antibody therapy, including UCLA's promising approaches
to prostate and kidney cancer, Figlin envisions using
immunotherapy a lot more in the future.
Figlin: I think what you're going to see as we move forward is - in quotes - in those "chemotherapy-responsive" diseases, that doesn't mean that immunotherapy can't be part of the package and I think in those "chemotherapy-responsive" diseases, immunotherapy is being added to enhance what chemotherapy has accomplished.
Narrator: For Science Today, I'm Larissa Branin.